AKTX · Akari Therapeutics Plc
$8.46
-0.24 (-2.70%)
At close · Jul 27
Going-concern doubt
— flagged May 19, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These factors raise substantial doubt about the Company’s ability to continue as a going concern for at least a one-year period following the issuance of these condensed consolidated financial statements.”View the 10-Q filed May 19, 2026
Market Cap
$14.81M
Shares
1.75M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$367.88K
-39.5%
FY2023
Net Income
-$17.3M
+12.6%
FY2025
Operating Margin
-4568.37%
-2618.7pp
FY2023
Diluted EPS
$0.00
FY2025
Operating Cash Flow
-$10.57M
+15.8%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 | FY2009 | FY2008 | FY2007 | FY2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | — | $367.88K | $607.68K | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| $3.46M | $2.82M | $6.98M | $5.45M | $3.92M | $9.13M | $8.82M | $8.74M | $11.8M | $23.29M | $17.31M | $5.8M | $1.62M | $1.28M | $1.48M | $841K | $247K | — | — | — | — | |
| — | — | — | $8.29M | $8.53M | — | — | — | — | — | — | — | $56K | — | — | — | — | — | — | — | — | |
| $8.74M | $9.28M | $9.66M | $11.36M | $13.53M | $8.08M | $9.16M | $8.22M | $11.69M | $11.8M | $9.94M | $5.5M | $303.1K | $2.33M | $2.18M | $1.41M | $545K | — | — | — | — | |
| — | — | $14K | $4000 | $4000 | $4126 | $8907 | $19.21K | $35.85K | $42.4K | $39.94K | $10.16K | $4942 | — | — | — | — | — | — | — | — | |
| — | -$50K | $1.72M | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| — | $17.28M | $21.64M | $16.81M | $12.46M | $17.21M | $17.98M | $16.96M | $20.79M | $37.78M | $27.25M | $30.58M | $1.92M | — | — | — | — | — | — | — | — | |
| -$29.51M | -$17.28M | -$21.64M | -$16.81M | -$11.85M | -$17.21M | -$17.98M | -$16.96M | -$20.79M | -$37.78M | -$27.25M | -$30.58M | -$1.92M | -$3.61M | -$3.67M | -$2.25M | -$792K | — | — | — | — | |
| — | — | — | -4568.37% | -1949.68% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| — | — | -$21.63M | -$16.8M | -$11.84M | -$17.21M | -$17.97M | -$16.94M | -$20.75M | -$37.74M | -$27.21M | -$30.57M | -$1.91M | — | — | — | — | — | — | — | — | |
| $106K | $100K | $244K | — | — | — | — | — | — | $0 | $0 | $3.05M | $5436 | — | — | — | — | — | — | — | — | |
| — | $1000 | $8000 | $82K | $46K | $10.6K | $13.62K | $5531 | $222.26K | $175.39K | $143.2K | $20.71K | $91 | — | — | — | — | — | — | — | — | |
| -$402K | -$1.03M | $1.85M | $6.8M | -$1.31M | -$210.1K | $899.36K | $116.92K | $285.84K | $2.38M | $9.11M | -$14.73M | -$28.25K | -$14K | -$601K | $128K | $117K | — | — | — | — | |
| — | -$18.3M | -$19.79M | -$10.01M | -$13.16M | -$17.42M | -$17.08M | -$16.85M | -$20.5M | -$35.4M | -$18.14M | -$45.32M | -$1.95M | — | — | — | — | — | — | — | — | |
| -$1.86M | -$1M | $0 | $0 | -$74K | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | — | — | — | — | — | — | — | — | |
| -$28.05M | -$17.3M | -$19.8M | -$10.01M | -$13.09M | -$17.42M | -$17.08M | -$16.85M | -$20.5M | -$35.4M | -$18.14M | -$45.32M | -$1.95M | -$3.62M | -$4.27M | -$2.12M | -$675K | -$1.01M | -$1.44M | -$3.13M | -$1.77M | |
| — | — | — | -2720.47% | -2153.88% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| — | — | — | — | — | — | — | — | — | — | — | — | -$9.65M | -$3.62M | -$4.3M | -$2.12M | -$675K | — | — | — | — | |
| -$28.04M | -$17.34M | -$19.49M | -$10.28M | -$13.15M | -$17.32M | -$17.38M | -$16.84M | -$20.62M | -$35.36M | -$18.58M | -$45.21M | -$1.87M | — | — | — | — | — | — | — | — | |
| USD/shares | — | $0.00 | $0.00 | $0.00 | -$29.60 | $0.00 | -$8.00 | -$8.00 | — | — | — | — | — | — | — | — | — | — | — | — | — |
| USD/shares | — | $0.00 | $0.00 | $0.00 | -$29.60 | $0.00 | -$8.00 | -$8.00 | — | — | — | — | — | — | — | — | — | — | — | — | — |
| shares | — | 1.68B | 597.2M | 244.72M | 442.8K | 5.37M | 3.95M | 2.29M | 1.93M | 1.56M | 1.47M | 1.07M | 106.89K | 26.34K | 15.57K | 14.9K | 14.28K | — | — | — | — |
| shares | — | 1.68B | 597.2M | 244.72M | 442.8K | 5.37M | 3.95M | 2.29M | 1.93M | 1.56M | 1.47M | 1.07M | 106.89K | 26.34K | 15.57K | 14.9K | 14.28K | — | — | — | — |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 21.02×
EV/EBIT
—
P/E (TTM)
—
Peer median 0.04×
Peer medians compare against the 217 similar-size Biotechnology companies (of 521 listed).